ROCKVILLE, Md., March 12, 2024 (GLOBE NEWSWIRE)
-- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and
commercialization of next-generation cell therapeutics and
innovative bioprocessing applications, today announced its fourth
quarter and full year ended December 31, 2023 financial results and
reiterated its 2024 guidance.
Fourth Quarter and Full Year
Highlights
- Total revenue of
$15.7 million in the fourth quarter of 2023, an increase of 26%
over the fourth quarter of 2022.
- Core business
revenue of $7.2 million in the fourth quarter of 2023, a decline of
32% over the fourth quarter of 2022.
- Strategic
Platform License (SPL) Program-related revenue was $8.5 million for
the fourth quarter of 2023, an increase of 359% over the fourth
quarter of 2022.
- Total revenue of
$41.3 million for the full year 2023, a decline of 7% over the full
year 2022.
- Core business
revenue of $29.8 million for the full year 2023, a decrease of 25%
over the full year 2022.
- SPL
Program-related revenue was $11.5 million for the full year 2023,
an increase of 148% over the full year 2022.
- Ended the year
with 23 active SPL agreements that allowed for over 160 potential
programs, 16 of which were active programs currently in the clinic
(defined as programs with at least a cleared IND or equivalent) and
1 of which was an active program currently commercial. With the
addition of three SPLs signed in 2024, the total number of SPLs now
stands at 26.
- Total cash, cash
equivalents and investments were $211.2 million as of December 31,
2023.
“In 2023, we navigated a challenging operating
environment in our industry, that included increased capital
conservatism and pipeline portfolio reevaluation among our
customers. Our team adapted well to the changing environment last
year, and I am confident in our ability to execute across the
business this year,” said Maher Masoud, President and CEO
of MaxCyte.
“We are pleased with our accomplishments and
progress in 2023, which included supporting the recent FDA approval
of CASGEVYTM by our client, Vertex Pharmaceuticals.
MaxCyte signed five new SPLs in 2023 and we have seen continued
momentum with three additional SPLs signed in January 2024. Our
pipeline of potential clients remains robust, and we look forward
to further expanding our portfolio of SPLs in 2024. The opportunity
in front of us in the cell therapy industry continues to
strengthen, and we will focus on executing in 2024 on our goal of
being the industry’s premier non-viral cell therapy platform.”
The following tables provide details regarding the sources of
our revenue for the periods presented.
| |
Three Months Ended |
|
|
|
Year Ended |
|
|
| |
December 31,
(Unaudited) |
|
|
|
December 31,
|
|
|
| |
2023 |
|
2022 |
|
% |
|
2023 |
|
2022 |
|
% |
|
(in thousands, except percentages) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cell therapy |
$ |
5,518 |
|
$ |
7,544 |
|
(27%) |
|
$ |
22,829 |
|
$ |
30,546 |
|
(25%) |
| Drug
discovery |
|
1,644 |
|
|
3,026 |
|
(46%) |
|
|
6,994 |
|
|
9,100 |
|
(23%) |
|
Program-related |
|
8,504 |
|
|
1,854 |
|
359% |
|
|
11,465 |
|
|
4,616 |
|
148% |
| Total revenue |
$ |
15,665 |
|
$ |
12,424 |
|
26% |
|
$ |
41,288 |
|
$ |
44,262 |
|
(7%) |
| |
Three Months Ended |
|
|
|
Year Ended |
|
|
| |
December 31,
(Unaudited) |
|
|
|
December 31,
|
|
|
| |
2023 |
|
2022 |
|
% |
|
2023 |
|
2022 |
|
% |
|
(in thousands, except percentages) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Instrument |
$ |
2,330 |
|
$ |
3,705 |
|
(37%) |
|
$ |
8,317 |
|
$ |
11,704 |
|
(29%) |
| PAs |
|
2,163 |
|
|
3,721 |
|
(42%) |
|
|
10,283 |
|
|
16,027 |
|
(36%) |
| Lease |
|
2,406 |
|
|
2,813 |
|
(14%) |
|
|
10,326 |
|
|
10,897 |
|
(5%) |
| Other |
|
263 |
|
|
331 |
|
(21%) |
|
|
897 |
|
|
1,018 |
|
(12%) |
| Total Core
Revenue |
$ |
7,162 |
|
$ |
10,570 |
|
(32%) |
|
$ |
29,823 |
|
$ |
39,646 |
|
(25%) |
In addition to revenue, management regularly reviews key business
metrics to evaluate our business, measure performance, identify
trends affecting our business, formulate financial projections and
make strategic decisions. As of the dates presented, these key
metrics were as follows:
|
|
|
|
|
| |
As of December 31, 2023 |
| |
2023 |
2022 |
2021 |
| Installed base of instruments
(sold or leased) |
683 |
616 |
502 |
| Core Revenue Generated by SPL
Clients as a % of Core Revenue |
48% |
42% |
40% |
| Number of active SPLs |
23 |
18 |
15 |
| Total number of licensed
potential programs (SPL clients only) |
>160 |
>125 |
>95 |
| Total number of active
licensed clinical programs under SPLs currently in the clinic
* |
16 |
16 |
15 |
| Total number of active
licensed programs under SPLs currently commercial * |
1 |
- |
- |
| Total potential pre-commercial
milestones under SPLs |
>$1.95 billion |
>$1.55 billion |
>$1.25 billion |
* Number of licensed clinical programs and
commercial programs under SPLs are by number of product candidates
and not by indication.
Fourth Quarter 2023 Financial
Results
Total revenue for the fourth quarter of 2023 was
$15.7 million, compared to $12.4 million in the fourth quarter of
2022, representing growth of 26%.
Core business revenue (sales and leases of
instrument and disposables to cell therapy and drug discovery
customers, excluding SPL Program-related revenue) for the fourth
quarter of 2023 was $7.2 million, compared to $10.6 million in the
fourth quarter of 2022, representing a decline of 32%.
Cell therapy revenue for the fourth quarter of
2023 was $5.5 million, compared to $7.5 million in the fourth
quarter of 2022, representing a decline of 27%. Drug discovery
revenue for the fourth quarter of 2023 was $1.6 million, compared
to $3.0 million in the fourth quarter of 2022, representing a
decline of 46%.
SPL Program-related revenue was $8.5 million in
the fourth quarter of 2023, as compared to $1.9 million in the
fourth quarter of 2022.
Gross profit for the fourth quarter of 2023 was
$14.1 million (90% gross margin), compared to $10.9 million (88%
gross margin) in the fourth quarter of 2022.
Operating expenses for the fourth quarter of
2023 were $22.2 million, compared to operating expenses of $17.6
million in the fourth quarter of 2022.
Fourth quarter 2023 net loss was $5.3 million
compared to net loss of $4.8 million for the same period in 2022.
EBITDA, a non-GAAP measure, was a loss of $7.0 million for the
fourth quarter of 2023, compared to a loss of $5.8 million for the
fourth quarter of 2022; stock-based compensation expense was $3.6
million in the fourth quarter of 2023 compared to $3.1 million in
the fourth quarter of 2022.
Full Year 2023 Financial
Results
Total revenue for 2023 was $41.3 million,
compared to $44.3 million in 2022, representing a decline of
7%.
Core business revenue (sales and leases of
instruments and disposables to cell therapy and drug discovery
customers, excluding SPL Program-related revenue) for 2023 was
$29.8 million, compared to $39.6 million for 2022, representing a
decline of 25%.
Cell therapy revenue for 2023 was $22.8 million,
compared to $30.5 million in 2022, representing a decline of 25%.
Drug discovery revenue for 2023 was $7.0 million, compared to $9.1
million in 2022, representing a decline of 23%.
SPL Program-related revenue was $11.5 million in
2023, as compared to $4.6 million in 2022.
Gross profit for 2023 was $36.5 million (89%
gross margin), compared to $39.2 million (88% gross margin) in the
prior year.
Operating expenses for 2023 were $84.8 million,
compared to operating expenses of $66.5 million in 2022.
Full year 2023 net loss was $37.9 million
compared to a loss of $23.6 million in 2022. 2023 EBITDA was a loss
of $44.1 million compared to a loss of $24.8 million in 2022; total
stock-based compensation for 2023 was $14.0 million, compared to
$11.8 million for 2022.
Total cash, cash equivalents and investments
were $211.2 million as of December 31, 2023, compared to $227.3
million as of December 31, 2022.
2024 Revenue Guidance
Management is reiterating 2024 revenue guidance
for core business revenue and SPL Program-related revenue.
Management expects full year 2024 core business
revenue to be flat to 5% growth compared to 2023, and SPL
Program-related revenue is expected to be approximately $3 million.
Our outlook for the full year does not include SPL Program-related
revenue from Vertex/CRISPR’s CASGEVYTM and reflects a
difficult year-over-year comparison from a client milestone
recognized in 2023 that was initially expected in 2024.
Management expects to end 2024 with $175 million
in total cash, cash equivalents and investments.
Webcast and Conference Call
Details
MaxCyte will host a conference call today, March
12, 2024, at 4:30 p.m. Eastern Time. Investors interested in
listening to the conference call are required to register online. A
live and archived webcast of the event will be available on the
“Events” section of the MaxCyte website at
https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte, we pursue cell engineering
excellence to maximize the potential of cells to improve patients’
lives. We have spent more than 20 years honing our expertise by
building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today’s processes to
innovate tomorrow’s solutions. Our ExPERT™ platform, which is based
on our Flow Electroporation® technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com and
follow us on Twitter and LinkedIn.
Non-GAAP Financial Measures
This press release contains EBITDA, which is a
non-GAAP measure defined as earnings before interest income and
expense, taxes, depreciation and amortization. MaxCyte believes
that EBITDA provides useful information to management and investors
relating to its results of operations. The company’s management
uses this non-GAAP measure to compare the company’s performance to
that of prior periods for trend analyses, and for budgeting and
planning purposes. The company believes that the use of EBITDA
provides an additional tool for investors to use in evaluating
ongoing operating results and trends and in comparing the company’s
financial measures with other companies, many of which present
similar non-GAAP financial measures to investors, and that it
allows for greater transparency with respect to key metrics used by
management in its financial and operational decision-making.
Management does not consider EBITDA in isolation
or as an alternative to financial measures determined in accordance
with GAAP. The principal limitation of EBITDA is that it excludes
significant expenses that are required by GAAP to be recorded in
the company’s financial statements. In order to compensate for
these limitations, management presents EBITDA together with GAAP
results. Non-GAAP measures should be considered in addition to
results prepared in accordance with GAAP, but should not be
considered a substitute for, or superior to, GAAP results. A
reconciliation table of net loss, the most comparable GAAP
financial measure, to EBITDA is included at the end of this
release. MaxCyte urges investors to review the reconciliation and
not to rely on any single financial measure to evaluate the
company’s business.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
statements about us and our industry involve substantial known and
unknown risks, uncertainties, and assumptions, including those
described in Item 1A under the heading “Risk Factors” and elsewhere
in our report on Form 10-K, that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. All statements other than
statements of historical facts contained in this press release,
including statements regarding our future results of operations or
financial condition, business strategy and plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements include, but are not limited to,
statements about the Company’s preliminary results of operations,
including fourth quarter and full year total revenue, core revenue,
and SPL program revenue and statements about possible or future
results of operations or financial position. In some cases, you can
identify forward-looking statements because they contain words such
as "may," “might,” "will," "could," "would," "should," "expect,"
"plan," "anticipate," "intend," "believe," “expect,” "estimate,"
“seek,” "predict," “future,” "project," "potential," "continue,"
“contemplate,” "target,” the negative of these words and similar
words or expressions. These statements are inherently uncertain,
and investors are cautioned not to unduly rely on these statements.
The forward-looking statements contained in this press release,
include, without limitation, statements concerning the following:
our expected future growth and success of our business model; the
size and growth potential of the markets for our products, and our
ability to serve those markets, increase our market share, and
achieve and maintain industry leadership; our ability to expand our
customer base and enter into additional SPL partnerships; our
expectation that our partners will have access to capital markets
to develop and commercialize their cell therapy programs; our
financial performance and capital requirements; the adequacy of our
cash resources and availability of financing on commercially
reasonable terms; our expectations regarding our ability to obtain
and maintain intellectual property protection for our products, as
well as our ability to operate our business without infringing the
intellectual property rights of others; our expectations regarding
general market and economic conditions that may impact investor
confidence in the biopharmaceutical industry and affect the amount
of capital such investors provide to our current and potential
partners; and our use of available capital resources.
These and other risks and uncertainties are
described in greater detail in Item 1A , entitled "Risk Factors,”
in our Annual Report on Form 10-K for the year ended December 31,
2023, filed with the Securities and Exchange Commission on or about
March 12, 2024, as well as in discussions of potential risks,
uncertainties, and other important factors in the other filings
that we make with the Securities and Exchange Commission from time
to time. These documents are available through the Investor Menu,
Financials section, under “SEC Filings” on the Investors page of
our website at http://investors.maxcyte.com. Any forward-looking
statements in this press release are based on our current beliefs
and opinions on the relevant subject based on information available
to us as of the date of such press release, and you should not rely
on forward-looking statements as predictions of future events. We
undertake no obligation to update any forward-looking statements
made in this press release to reflect events or circumstances after
the date of this press release or to reflect new information or the
occurrence of unanticipated events, except as required by law.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
venes@spectrumscience.com
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
|
MaxCyte, Inc.
Consolidated Balance Sheets
(in thousands, except share and per share
amounts) |
| |
|
| |
Year ended December 31, |
| |
2023 |
|
2022 |
| Assets |
|
|
|
|
|
| Current
assets: |
|
|
|
|
|
|
Cash and cash equivalents |
$ |
46,506 |
|
|
$ |
11,065 |
|
| Short-term investments, at
amortized cost |
|
121,782 |
|
|
|
216,275 |
|
| Accounts receivable, net |
|
5,778 |
|
|
|
11,175 |
|
| Accounts receivable –
TIA* |
|
- |
|
|
|
1,912 |
|
| Inventory |
|
12,229 |
|
|
|
8,581 |
|
| Prepaid expenses and other
current assets |
|
3,899 |
|
|
|
3,258 |
|
| Total current
assets |
|
190,194 |
|
|
|
252,266 |
|
| |
|
|
|
|
|
| Investments, non-current, at
amortized cost |
|
42,938 |
|
|
|
— |
|
| Property and equipment,
net |
|
23,513 |
|
|
|
23,725 |
|
| Right-of-use asset - operating
leases |
|
11,241 |
|
|
|
9,853 |
|
| Other assets |
|
388 |
|
|
|
809 |
|
| Total
assets |
$ |
268,274 |
|
|
$ |
286,653 |
|
| |
|
|
|
|
|
| Liabilities and
stockholders’ equity |
|
|
|
|
|
| Current
liabilities: |
|
|
|
|
|
| Accounts payable |
$ |
743 |
|
|
$ |
292 |
|
| Accrued expenses and
other |
|
11,269 |
|
|
|
8,265 |
|
| Operating lease liability,
current |
|
774 |
|
|
|
157 |
|
| Deferred revenue, current
portion |
|
5,069 |
|
|
|
6,713 |
|
| Total current
liabilities |
|
17,855 |
|
|
|
15,427 |
|
| |
|
|
|
|
|
| Operating lease liability, net
of current portion |
|
17,969 |
|
|
|
15,938 |
|
| Other liabilities |
|
283 |
|
|
|
1,320 |
|
| Total
liabilities |
|
36,107 |
|
|
|
32,685 |
|
| |
|
|
|
|
|
| Commitments and
contingencies |
|
|
|
|
|
| Stockholders’
equity |
|
|
|
|
|
| Preferred stock, $0.01 par
value; 5,000,000 shares authorized and no shares issued and
outstanding at December 31, 2023 and December 31, 2022 |
|
— |
|
|
|
— |
|
| Common stock, $0.01 par value;
400,000,000 shares authorized, 103,961,670 and 102,397,913 shares
issued and outstanding at December 31, 2023 and December 31, 2022,
respectively |
|
1,040 |
|
|
|
1,024 |
|
| Additional paid-in
capital |
|
406,925 |
|
|
|
390,819 |
|
| Accumulated deficit |
|
(175,798 |
) |
|
|
(137,875 |
) |
| Total stockholders’
equity |
|
232,167 |
|
|
|
253,968 |
|
| Total liabilities and
stockholders’ equity |
$ |
268,274 |
|
|
$ |
286,653 |
|
* Tenant improvement allowance (“TIA”)
|
|
MaxCyte, Inc.
Consolidated Statements of Operations
(in thousands, except share and per share
amounts) |
| |
|
|
|
| |
Three Months Ended December 31, |
|
Year Ended December 31, |
| |
2023
(Unaudited) |
|
2022
(Unaudited) |
|
2023 |
|
|
2022 |
|
|
Revenue |
$ |
15,666 |
|
|
$ |
12,424 |
|
|
$ |
41,288 |
|
|
$ |
44,261 |
|
| Cost of goods sold |
|
1,573 |
|
|
|
1,547 |
|
|
|
4,742 |
|
|
|
5,098 |
|
| Gross
profit |
|
14,093 |
|
|
|
10,877 |
|
|
|
36,546 |
|
|
|
39,163 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
| Operating
expenses: |
|
|
|
|
|
|
|
|
|
|
|
| Research and development |
|
5,842 |
|
|
|
5,728 |
|
|
|
23,817 |
|
|
|
19,514 |
|
| Sales and marketing |
|
7,196 |
|
|
|
5,377 |
|
|
|
26,975 |
|
|
|
18,653 |
|
| General and
administrative |
|
8,087 |
|
|
|
5,649 |
|
|
|
30,068 |
|
|
|
25,829 |
|
| Depreciation and
amortization |
|
1,063 |
|
|
|
873 |
|
|
|
3,985 |
|
|
|
2,528 |
|
| Total operating
expenses |
|
22,188 |
|
|
|
17,627 |
|
|
|
84,845 |
|
|
|
66,524 |
|
| Operating
loss |
|
(8,095 |
) |
|
|
(6,750 |
) |
|
|
(48,299 |
) |
|
|
(27,361 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
| Other income and
expense: |
|
|
|
|
|
|
|
|
|
|
|
| Other expense |
|
— |
|
|
|
(11 |
) |
|
|
— |
|
|
|
(127 |
) |
| Interest income |
|
2,818 |
|
|
|
1,952 |
|
|
|
10,376 |
|
|
|
3,917 |
|
| Total other
income |
|
2,818 |
|
|
|
1,941 |
|
|
|
10,376 |
|
|
|
3,790 |
|
| Net loss |
$ |
(5,277 |
) |
|
$ |
(4,809 |
) |
|
$ |
(37,923 |
) |
|
$ |
(23,571 |
) |
| Basic and diluted net
loss per share |
$ |
(0.05 |
) |
|
$ |
(0.05 |
) |
|
$ |
(0.37 |
) |
|
$ |
(0.23 |
) |
| Weighted average
shares outstanding, basic and
diluted |
|
103,703,240 |
|
|
|
102,120,812 |
|
|
|
103,268,502 |
|
|
|
101,702,664 |
|
|
|
MaxCyte, Inc.
Consolidated Statements of Cash Flows
(in thousands) |
| |
|
| |
Year ended December 31, |
| |
2023 |
|
2022 |
| Cash flows from
operating activities: |
|
|
|
|
|
|
Net loss |
$ |
(37,923 |
) |
|
$ |
(23,571 |
) |
| |
|
|
|
|
|
| Adjustments to reconcile net
loss to net cash used in operating activities: |
|
|
|
|
|
| Depreciation and
amortization |
|
4,171 |
|
|
|
2,698 |
|
| Non-cash lease expense |
|
395 |
|
|
|
767 |
|
| Net book value of consigned
equipment sold |
|
94 |
|
|
|
76 |
|
| Loss on disposal of fixed
assets |
|
30 |
|
|
|
139 |
|
| Stock-based compensation |
|
13,979 |
|
|
|
11,752 |
|
| Bad debt expense |
|
171 |
|
|
|
— |
|
| Change in excess/obsolete
inventory reserve |
|
697 |
|
|
|
— |
|
| Amortization of discounts on
investments |
|
(7,120 |
) |
|
|
(2,667 |
) |
| |
|
|
|
|
|
| Changes in operating assets
and liabilities: |
|
|
|
|
|
| Accounts receivable |
|
5,226 |
|
|
|
(4,569 |
) |
| Accounts receivable - TIA |
|
1,912 |
|
|
|
(1,912 |
) |
| Inventory |
|
(4,534 |
) |
|
|
(3,493 |
) |
| Prepaid expense and other
current assets |
|
(641 |
) |
|
|
320 |
|
| Other assets |
|
421 |
|
|
|
(492 |
) |
| Accounts payable, accrued
expenses and other |
|
3,252 |
|
|
|
(150 |
) |
| Operating lease liability |
|
(133 |
) |
|
|
5,482 |
|
| Deferred revenue |
|
(1,644 |
) |
|
|
(34 |
) |
| Other liabilities |
|
(39 |
) |
|
|
871 |
|
| Net cash used in operating
activities |
|
(21,686 |
) |
|
|
(14,783 |
) |
| |
|
|
|
|
|
| Cash flows from
investing activities: |
|
|
|
|
|
| Purchases of investments |
|
(255,095 |
) |
|
|
(290,942 |
) |
| Maturities of investments |
|
313,770 |
|
|
|
284,596 |
|
| Purchases of property and
equipment |
|
(3,700 |
) |
|
|
(18,477 |
) |
| Proceeds from sale of
equipment |
|
9 |
|
|
|
— |
|
| Net cash provided by (used in)
investing activities |
|
54,984 |
|
|
|
(24,823 |
) |
| |
|
|
|
|
|
| Cash flows from
financing activities: |
|
|
|
|
|
| Proceeds from exercise of
stock options |
|
1,874 |
|
|
|
2,888 |
|
| Proceeds from issuance of
common stock under employee stock purchase plan |
|
269 |
|
|
|
— |
|
| Net cash provided by financing
activities |
|
2,143 |
|
|
|
2,888 |
|
| Net increase (decrease) in
cash and cash equivalents |
|
35,441 |
|
|
|
(36,718 |
) |
| Cash and cash equivalents,
beginning of year |
|
11,065 |
|
|
|
47,783 |
|
| Cash and cash equivalents, end
of year |
$ |
46,506 |
|
|
$ |
11,065 |
|
|
|
Unaudited Reconciliation of Net Loss to
EBITDA
(in
thousands)
(Unaudited) |
| |
| |
Three Months Ended |
|
Year Ended |
| |
December 31, |
|
December 31, |
| |
2023 |
|
2022 |
|
2023 |
|
2022 |
| (in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
$ |
(5,277 |
) |
|
$ |
(4,809 |
) |
|
$ |
(37,923 |
) |
|
$ |
(23,571 |
) |
| Depreciation and amortization
expense |
|
1,102 |
|
|
|
920 |
|
|
|
4,171 |
|
|
|
2,698 |
|
| Interest income |
|
(2,818 |
) |
|
|
(1,952 |
) |
|
|
(10,376 |
) |
|
|
(3,917 |
) |
| Income taxes |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| EBITDA |
$ |
(6,993 |
) |
|
$ |
(5,841 |
) |
|
$ |
(44,128 |
) |
|
$ |
(24,790 |
) |
Maxcyte (LSE:MXCN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Maxcyte (LSE:MXCN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
